OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
RXRX
Recursion Pharmaceuticals, Inc.
There isn't enough reported data to score RXRX yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RXRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
RXRX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RXRX PE Valuation
RXRX has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
RXRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RXRX's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over RXRX on earnings quality, reporting a profit while its opponent remains loss making.
RXRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.86 | +$0.97 |
| Q2 2026 | -$1.00 | +$0.81 |
| Q1 2026 | -$1.16 | +$0.64 |
| Q4 2025 | -$1.44 | +$0.25 |
| Q3 2025 | -$1.83 | -$0.27 |
| Q2 2025 | -$1.81 | -$0.16 |
| Q1 2025 | -$1.80 | -$0.17 |
| Q4 2024 | -$1.69 | -$0.11 |
RXRX is still losing money, but far less than before: $0.86 per share over the past year, against $2.07 at its worst in late 2021.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over RXRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over RXRX on profitability, with a higher operating margin.
RXRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.6M | +258% |
| Q2 2026 | $7.7M | -60% |
| Q1 2026 | $6.5M | -56% |
| Q4 2025 | $35.5M | +682% |
| Q3 2025 | $5.2M | -80% |
| Q2 2025 | $19.2M | +33% |
| Q1 2025 | $14.7M | +6.9% |
| Q4 2024 | $4.5M | -58% |
RXRX's revenue is growing: $19M last quarter, up 258% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -664% | +2664 points |
| Q2 2026 | -1760% | -843 points |
| Q1 2026 | -1986% | -688 points |
| Q4 2025 | -305% | +3738 points |
| Q3 2025 | -3328% | -2951 points |
| Q2 2025 | -917% | -219 points |
| Q1 2025 | -1298% | -599 points |
| Q4 2024 | -4042% | -3134 points |
RXRX's operating margin was −664% last quarter, up 2664 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over RXRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
RXRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$77.8M | +$39.8M |
| Q2 2026 | -$106M | -$26.4M |
| Q1 2026 | -$81.4M | +$52.4M |
| Q4 2025 | -$47.3M | +$69.4M |
| Q3 2025 | -$117.6M | -$53.8M |
| Q2 2025 | -$79.6M | +$3.8M |
| Q1 2025 | -$133.8M | -$24.8M |
| Q4 2024 | -$116.7M | -$40.6M |
RXRX has burned cash in almost every quarter: −$312M over the past year, against −$448M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RXRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +10.5M shares |
| 1 year | +21% | +96M shares |
| 3 years | +170% | +342M shares |
| 5 years | +2257% | +520M shares |
| Available history | +223% | +375M shares |
RXRX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RXRX Net Leverage
RXRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RXRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.7 | Neutral |
| Stochastic | 31.6 | Neutral |
RXRX's weekly RSI is 47 (neutral) and its Stochastic is 32 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RXRX PE vs Healthcare Sector
RXRX has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RXRX on trend strength, trading above more of its moving averages.
RXRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.78 | 12% below |
| 20 week MA | $3.52 | 5.4% below |
| 50 week MA | $3.62 | 8% below |
| 100 week MA | $4.69 | 29% below |
| 200 week MA | $6.45 | 48% below |
RXRX is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RXRX on returns for 2026, with the stronger performance.
RXRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.3 | $16.8 | -46% |
| 2022 | $16.8 | $7.51 | -55% |
| 2023 | $7.51 | $9.86 | +31% |
| 2024 | $9.86 | $7.39 | -25% |
| 2025 | $7.39 | $4.25 | -42% |
| 2026 YTD | $4.25 | $3.33 | -22% |
RXRX has finished lower in four of the last five years. It's down 22% so far in 2026.